Corcept Historical Cash Flow
| CORT Stock | USD 58.60 0.02 0.03% |
Analysis of Corcept Therapeutics cash flow over time is an excellent tool to project Corcept Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Liabilities of 3.1 M or End Period Cash Flow of 142.3 M as it is a great indicator of Corcept Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Corcept Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corcept Therapeutics is a good buy for the upcoming year.
Corcept |
About Corcept Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Corcept balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Corcept's non-liquid assets can be easily converted into cash.
Corcept Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Corcept Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Corcept Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Corcept Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Corcept Therapeutics' Change To Inventory is comparatively stable compared to the past year. Dividends Paid is likely to gain to about 28.8 M in 2024, whereas Change To Liabilities is likely to drop slightly above 3.1 M in 2024.
Corcept Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Corcept Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corcept Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 1.1M | 1.2M | 469K | 413K | 139K | 132.1K | |
| Total Cash From Financing Activities | (28.6M) | 12.2M | (302.6M) | (17.3M) | (148.7M) | (141.3M) | |
| Change To Liabilities | 1.9M | 8.3M | 1.6M | 4.8M | 5.5M | 3.1M | |
| End Period Cash Flow | 31.3M | 76.2M | 77.6M | 66.3M | 135.6M | 142.3M | |
| Change In Cash | (10.4M) | 44.9M | 1.4M | (11.3M) | 69.2M | 72.7M | |
| Free Cash Flow | 135.0M | 150.7M | 167.4M | 119.9M | 126.9M | 133.2M | |
| Change In Working Capital | (4.7M) | (5.4M) | (57K) | 6.0M | 8.2M | 8.6M | |
| Begin Period Cash Flow | 41.6M | 31.3M | 76.2M | 77.6M | 66.3M | 39.3M | |
| Total Cashflows From Investing Activities | (117.8M) | (119.3M) | 136.1M | (114.3M) | (102.9M) | (97.7M) | |
| Other Cashflows From Financing Activities | 2.3M | 22.2M | (6.6M) | 4.4M | (3.3M) | (3.1M) | |
| Depreciation | 2.2M | 2.2M | 3.1M | 3.0M | 2.4M | 2.5M | |
| Other Non Cash Items | (1.7M) | 1.5M | 5.1M | 1.4M | (9.1M) | (8.7M) | |
| Total Cash From Operating Activities | 136.1M | 152.0M | 167.9M | 120.3M | 127.0M | 133.4M | |
| Net Income | 94.2M | 106.0M | 112.5M | 101.4M | 106.1M | 111.4M | |
| Stock Based Compensation | 29.3M | 33.5M | 42.9M | 42.4M | 48.9M | 79.3M | |
| Sale Purchase Of Stock | (31.0M) | (9.9M) | (296.0M) | (21.7M) | (145.4M) | (138.2M) | |
| Change To Inventory | (1.0M) | (3.5M) | 3.4M | 1.2M | 1.3M | 1.3M | |
| Cash And Cash Equivalents Changes | 10.6M | (10.4M) | 44.9M | 1.4M | 1.6M | 1.6M | |
| Cash Flows Other Operating | (6.8M) | (3.4M) | (875K) | 3.4M | 3.0M | 3.2M | |
| Change To Account Receivables | (2.3M) | (6.3M) | (1.4M) | (3.4M) | (10.1M) | (9.6M) | |
| Change To Netincome | 46.2M | 47.8M | 47.3M | 9.9M | 11.4M | 14.5M | |
| Change Receivables | 10.6M | (2.3M) | (6.3M) | (1.4M) | (1.3M) | (1.3M) | |
| Investments | (116.7M) | (118.0M) | 136.6M | (114.3M) | 56.6M | 59.4M | |
| Change To Operating Activities | (715K) | 1.3M | 1.5M | (5.2M) | (4.7M) | (4.4M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.